Dermata Therapeutics, Inc.

Founded in 2014 and headquartered in San Diego, California, Dermata Therapeutics is a late-stage pharmaceutical company focused on developing topical treatments for medical dermatology and aesthetic applications. The company's lead product candidate, XYNGARI, is currently in Phase 3 clinical development for moderate-to-severe acne and has completed Phase 1b proof-of-concept trials for mild-to-moderate psoriasis. A second product candidate, DMT410, has completed Phase 1b studies for axillary hyperhidrosis and aesthetic skin conditions.

Dermata has established a clinical collaboration with Revance Therapeutics to evaluate XYNGARI as a combination therapy with DAXXIFY, a botulinum toxin product, through a multi-center clinical trial. This partnership represents a potential path to expand the commercial applications of its lead asset.

The company operates with a lean structure of eight full-time employees. As a clinical-stage pharmaceutical developer, Dermata currently generates revenue primarily through research collaborations and does not have commercialized products. The company is listed on the Nasdaq exchange, incorporated in Delaware.